Insights from the PLCO trial about prostate cancer screening. Issue 4 (1st December 2016)

• Record Type: Journal Article
• Authors: Gulati, Roman; Albertsen, Peter C.
• Is Part Of: Cancer. Volume 123:Issue 4(2017)
• Page Start: 546
• Page End: 548
• Publication Date: 2016-12-01
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.30472
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Updated results from the US‐based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial show durability of earlier findings demonstrating that up to 6 rounds of annual prostate‐specific antigen testing does not reduce prostate cancer mortality in comparison with historical screening practice. Although trials in Europe have estimated that certain screening programs can reduce prostate cancer mortality in comparison with no screening, the PLCO Cancer Screening Trial demonstrates that there are limits to the benefit that can be achieved. See also pages 592‐9.